[More evidence against COX-2 inhibitors. The risk of severe cardiovascular complications more and more obvious].
Hjemdahl
Paul
P
Institutionen för medicin, enheten för kliniskfarmakologi, Karolinska institutet och Karolinska Universitetssjukhuset Solna, Stockholm. paul.hjemdahl@ki.se
D002318:Cardiovascular Diseases / Q000139:chemically induced*; D002986:Clinical Trials as Topic; D052246:Cyclooxygenase 2 Inhibitors / Q000009:adverse effects*; D019317:Evidence-Based Medicine; D006801:Humans; D012307:Risk Factors
D052246:Cyclooxygenase 2 Inhibitors